Trancart, Stéphanie <br/><br/>
Presence of lamivudine or emtricitabine is associated with reduced emergence of nonnucleoside reverse transcriptase inhibitor mutations in an efavirenz-based intermittent antiretroviral treatment regimen.  [electronic resource] 

 -  Antimicrobial agents and chemotherapy  Mar 2012 
 - 1655-7 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1098-6596 
<br/><br/><label>Standard No.: </label>10.1128/AAC.05452-11  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Alkynes<br/>Amino Acid Substitution<br/>Anti-HIV Agents--blood<br/>Benzoxazines--blood<br/>Chromatography, High Pressure Liquid<br/>Cyclopropanes<br/>Deoxycytidine--administration & dosage<br/>Drug Combinations<br/>Drug Resistance, Viral<br/>Emtricitabine<br/>HIV Infections--drug therapy<br/>HIV Reverse Transcriptase--antagonists & inhibitors<br/>HIV-1--drug effects<br/>Half-Life<br/>Humans<br/>Lamivudine--administration & dosage<br/>Male<br/>Mutation<br/>Reverse Transcriptase Inhibitors--blood<br/>Viral Load--drug effects